How Q4 Beats And Guidance Debates Are Reframing The Omda (OB:OMDA) Investment Story

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.

Omda’s Fair Value price target has been reaffirmed at NOK 59.0, keeping the core valuation anchor steady despite recent tweaks to the underlying model. That stability comes as analysts weigh Q4 revenue and EBITDA beats and strong program momentum against concerns around Healthcare Information Technology valuation pressure and client concentration. As you read on, you will see how these data points and opinions are shaping the evolving narrative around Omda and what to watch next.

Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Omda.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

Canaccord, Morgan Stanley, Goldman Sachs and Barclays all keep positive ratings in their latest notes, signaling that they still see appeal in Omda even after revising price targets. Several firms, including Canaccord and Morgan Stanley, highlight strong Q4 execution, pointing to an 8% revenue beat, a $7m EBITDA beat and what they describe as momentum across all programs. Barclays and BMO call out the potential for upside if management delivers against what they view as conservative elements in the fiscal 2026 outlook, helped by GLP 1 and multi condition adoption. Barclays also mentions accelerated Q4 growth in revenue and members, and suggests that the revenue outlook leaves room for upside, which some investors may view as an attractive setup.

🐻 Bearish Takeaways

Across Evercore ISI, BMO, Canaccord, Morgan Stanley, Barclays and Goldman Sachs, the common thread is lower price targets, which reflects valuation pressure on Healthcare Information Technology and more cautious assumptions in updated models. Wells Fargo’s Equal Weight initiation at a US$17 price target flags client concentration and ownership structure as complications for the competitive position, framing Omda as a more balanced risk or reward idea.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!OB:OMDA 1-Year Stock Price Chart

We've flagged 1 risk for Omda. See which could impact your investment.

What's in the News

Omda AS reiterated its 2026 earnings guidance, signaling that the company is keeping its existing profitability targets in place. The company maintained its expected 2026 revenue range at NOK 500m to NOK 525m, with no changes to its multi year financial targets. Recent commentary around Omda continues to reference the reaffirmed guidance as a key reference point for assessing the company’s medium term plans.

Story Continues

How This Changes the Fair Value For Omda

Fair Value is reaffirmed at NOK 59.0, unchanged from the prior NOK 59 level. The revenue growth assumption moves from 5.55% to 4.16%. The long term profit margin assumption moves from 11.10% to 10.96%. The future P/E multiple moves from 24.64x to 25.05x. The discount rate moves from 9.11% to 9.22%.

Never Miss an Update: Follow The Narrative

Narratives link a company's story to a financial forecast and fair value, so you can see how business milestones connect to the numbers. They update as new data comes in, keeping the investment case current.

Head over to the Simply Wall St Community and follow the Narrative on Omda to stay up to date on:

How Omda's focus on healthcare and emergency response software, recurring revenues and low churn supports its multi condition growth story across 26 countries. What ongoing healthcare digitization, AI and data analytics adoption, and disciplined M&A could mean for Omda's revenue mix and earnings profile. How exposure to publicly funded contracts, tighter data privacy rules, cyber risks and rising R&D needs could pressure margins or future growth expectations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include OMDA.OL.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments